Available 24/7 for Urgent On-Site or Virtual Consulting
Navigating a medical device contract manufacturer FDA inspection requires a rigorous alignment between sponsor expectations and facility operations. As we move into 2026, the risks associated with outsourced manufacturing—ranging from purchasing controls to technical documentation gaps—have intensified. This guide identifies the top inspectional risks and provides a blueprint for maintaining a state of perpetual audit readiness.
In the high-stakes world of pharmaceutical and medical device manufacturing, data is the most valuable asset. This 2026 guide breaks down the core components of an FDA data integrity inspection, identifying the specific questions investigators prioritize during audits. From ALCOA+ principles to electronic audit trails, discover how to protect your facility from 483 observations and warning letters.
As the frontier of regenerative medicine expands, navigating cell and gene therapy FDA inspections has become a critical milestone for biotech innovators. This 2026 guide explores what investigators prioritize—from aseptic processing and viral clearance to complex chain-of-identity protocols. Learn how to align your quality systems with CBER expectations and ensure your advanced therapy reaches the market securely.
Navigating a regulatory audit requires a precise understanding of the legal boundaries governing federal oversight. This comprehensive 2026 guide explores the extent of FDA inspection authority, identifying exactly what investigators can legally request, which records are shielded from review, and how manufacturers can protect their interests while remaining fully compliant during on-site assessments.
Ensuring regulatory compliance requires more than just hiring a third-party manufacturer. This guide explores the critical gaps in CDMO FDA inspection readiness, highlighting the common mistakes sponsors make during the oversight process. Learn how to strengthen your quality agreements, improve data integrity, and ensure your external partners remain audit-ready in the evolving 2026 landscape.
As the regulatory landscape shifts, the introduction of the FDA one day inspections biologics protocol has sent ripples through the pharmaceutical industry. This 2026 guide examines the strategic shift toward rapid assessments, the technological requirements for biologics manufacturers, and how firms must adapt their quality management systems to survive a compressed inspectional timeline.
The FDA has announced a new “One-Day Inspectional Assessment” pilot program aimed at increasing oversight efficiency through rapid, targeted inspections.
Maintaining accurate records is the primary requirement for cGMP compliance. However, many firms struggle with systemic paperwork errors. This guide analyzes the most frequent Documentation Failures FDA investigators uncover during audits, ranging from missing signatures to backdated entries. Learn how to identify these gaps through gap analysis and protect your facility from regulatory enforcement and 483 observations.
Navigating an agency audit requires a deep understanding of how investigators evaluate your data. This guide explores the critical elements of Laboratory Records FDA scrutiny, focusing on raw data, audit trails, and ALCOA+ principles. Discover how to identify gaps in your documentation, manage forensic audits, and protect your facility from Warning Letters through proactive laboratory record management.
Regulatory experts agree that proactive identification of compliance weaknesses is the only way to safeguard a life sciences facility. This guide explains how Gap Analysis Prevents FDA Enforcement by pinpointing systemic vulnerabilities before investigators arrive. Explore the methods for auditing your Quality Management System, securing data integrity, and building a robust defense against 483 observations.
Your trusted partner for FDA compliance and inspection readiness. With former ex-FDA’ers on our team, we provide the expertise and confidence you need to succeed.